Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report

A 35-year-old male was diagnosed with chronic myeloid leukemia in the chronic phase and was prescribed 100 mg daily dasatinib. However, dasatinib was discontinued due to thrombocytopenia, and within six months, the disease progressed to the lymphoid blastic phase. Hyper-cyclophosphamide, vincristine...

Descripción completa

Detalles Bibliográficos
Autores principales: Komeno, Yukiko, Uchida, Naoyuki, Satoh, Yumiko, Uryu, Hideki, Iwata, Yuko, Masuda, Akiko, Iihara, Kuniko, Yatomi, Yutaka, Taniguchi, Shuichi, Ryu, Tomiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452986/
https://www.ncbi.nlm.nih.gov/pubmed/28599428
http://dx.doi.org/10.3892/ol.2017.5989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452986/
https://www.ncbi.nlm.nih.gov/pubmed/28599428
http://dx.doi.org/10.3892/ol.2017.5989

Ejemplares similares